CU6Health CareCompany Update27 Oct 202627 October 2026· 2 min read
Clarity Pharmaceuticals (ASX: CU6) Doses 383 Patients in Phase III CLARIFY Trial
Clarity Pharmaceuticals has dosed the planned 383 participants in its registrational Phase III CLARIFY trial. Topline results are expected in the first half of 2027.